Creso Pharma’s strong quarter marks evolution into a broader-based pharmaceutical company: chairman
The surge in revenue along with business ties-ups across major global markets following regulatory changes and the acquisition of an established psychedelics company could transform it into a broader-based pharma company. CERES Natural Remedies flagship store in Vermont, US
Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has witnessed a strong first quarter, with total revenue rising by 237% from the preceding quarter, marking the company’s evolution into a broader-based pharmaceutical company, according to non-executive chairman Adam Blumenthal.
The surge in the group’s revenue growth during the quarter highlighted the growing demand for the company’s products, as regulatory shifts across cannabis industries globally continue to unlock growth opportunities.
Creso Pharma Ltd welcomes strong progress made by target acquisition Halucenex Life Sciences Inc
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Baystreet ca - Mycology Interest on the Rise as Researchers Unearth More Benefits of Functional Mushroom Products
baystreet.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baystreet.ca Daily Mail and Mail on Sunday newspapers.
In other industry news of note:
Mydecine Innovations Group (CSE:MYCO) (MYCO.CNQ), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, recently announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. As part of the agreement, ProPharma Group will provide regulatory advisement as the company seeks approval from the Food and Drug Administration (FDA) for its drug development platform as well as the Company s various stage clinical trials. ProPharma Group is a globally recognized firm with a strong track record of working with life sciences and biopharma companies to ensure full compliance with all FDA regulations, including all necessary steps for eventual global federal approvals, said Josh Bartch, CEO and Co-Founder of Mydecine. Mydecine cur